Ran S - Search Results

1

Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells.

Castro-Rivera E, Ran S, Brekken RA, Minna JD. Castro-Rivera E, et al. Among authors: ran s. Cancer Res. 2008 Oct 15;68(20):8295-303. doi: 10.1158/0008-5472.CAN-07-6601. Cancer Res. 2008. PMID: 18922901 Free PMC article.

2

Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature.

Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE. Ran S, et al. Cancer Res. 1998 Oct 15;58(20):4646-53. Cancer Res. 1998. PMID: 9788617

3

Increased exposure of anionic phospholipids on the surface of tumor blood vessels.

Ran S, Downes A, Thorpe PE. Ran S, et al. Cancer Res. 2002 Nov 1;62(21):6132-40. Cancer Res. 2002. PMID: 12414638

4

Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect.

Castro-Rivera E, Ran S, Thorpe P, Minna JD. Castro-Rivera E, et al. Among authors: ran s. Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11432-7. doi: 10.1073/pnas.0403969101. Epub 2004 Jul 23. Proc Natl Acad Sci U S A. 2004. PMID: 15273288 Free PMC article.

5

Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.

Whitehurst B, Flister MJ, Bagaitkar J, Volk L, Bivens CM, Pickett B, Castro-Rivera E, Brekken RA, Gerard RD, Ran S. Whitehurst B, et al. Among authors: ran s. Int J Cancer. 2007 Nov 15;121(10):2181-91. doi: 10.1002/ijc.22937. Int J Cancer. 2007. PMID: 17597103 Free article.

6

Tumor suppressor function of Rab25 in triple-negative breast cancer.

Cheng JM, Volk L, Janaki DK, Vyakaranam S, Ran S, Rao KA. Cheng JM, et al. Among authors: ran s. Int J Cancer. 2010 Jun 15;126(12):2799-812. doi: 10.1002/ijc.24900. Int J Cancer. 2010. PMID: 19795443 Free article.

7

A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model.

Zhang W, Ran S, Sambade M, Huang X, Thorpe PE. Zhang W, et al. Among authors: ran s. Angiogenesis. 2002;5(1-2):35-44. doi: 10.1023/a:1021540120521. Angiogenesis. 2002. PMID: 12549858

8

Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice.

Ran S, He J, Huang X, Soares M, Scothorn D, Thorpe PE. Ran S, et al. Clin Cancer Res. 2005 Feb 15;11(4):1551-62. doi: 10.1158/1078-0432.CCR-04-1645. Clin Cancer Res. 2005. PMID: 15746060

9

TLR4 is a novel determinant of the response to paclitaxel in breast cancer.

Rajput S, Volk-Draper LD, Ran S. Rajput S, et al. Among authors: ran s. Mol Cancer Ther. 2013 Aug;12(8):1676-87. doi: 10.1158/1535-7163.MCT-12-1019. Epub 2013 May 29. Mol Cancer Ther. 2013. PMID: 23720768 Free PMC article.

10

CXM: a new tool for mapping breast cancer risk in the tumor microenvironment.

Flister MJ, Endres BT, Rudemiller N, Sarkis AB, Santarriaga S, Roy I, Lemke A, Geurts AM, Moreno C, Ran S, Tsaih SW, De Pons J, Carlson DF, Tan W, Fahrenkrug SC, Lazarova Z, Lazar J, North PE, LaViolette PS, Dwinell MB, Shull JD, Jacob HJ. Flister MJ, et al. Among authors: ran s. Cancer Res. 2014 Nov 15;74(22):6419-29. doi: 10.1158/0008-5472.CAN-13-3212. Epub 2014 Aug 29. Cancer Res. 2014. PMID: 25172839 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

386 results

Search Page